JP2021521828A5 - - Google Patents

Info

Publication number
JP2021521828A5
JP2021521828A5 JP2020559481A JP2020559481A JP2021521828A5 JP 2021521828 A5 JP2021521828 A5 JP 2021521828A5 JP 2020559481 A JP2020559481 A JP 2020559481A JP 2020559481 A JP2020559481 A JP 2020559481A JP 2021521828 A5 JP2021521828 A5 JP 2021521828A5
Authority
JP
Japan
Prior art keywords
cells
salt
hydroxycitric acid
cultured
isolated
Prior art date
Application number
JP2020559481A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019209715A5 (https=
JP2021521828A (ja
JP7342030B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/028513 external-priority patent/WO2019209715A1/en
Publication of JP2021521828A publication Critical patent/JP2021521828A/ja
Publication of JPWO2019209715A5 publication Critical patent/JPWO2019209715A5/ja
Publication of JP2021521828A5 publication Critical patent/JP2021521828A5/ja
Application granted granted Critical
Publication of JP7342030B2 publication Critical patent/JP7342030B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020559481A 2018-04-24 2019-04-22 ヒドロキシクエン酸および/またはその塩を使用してt細胞集団を産生する方法 Active JP7342030B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862661941P 2018-04-24 2018-04-24
US62/661,941 2018-04-24
PCT/US2019/028513 WO2019209715A1 (en) 2018-04-24 2019-04-22 Methods of producing t cell populations using hydroxycitric acid and/or a salt thereof

Publications (4)

Publication Number Publication Date
JP2021521828A JP2021521828A (ja) 2021-08-30
JPWO2019209715A5 JPWO2019209715A5 (https=) 2022-05-02
JP2021521828A5 true JP2021521828A5 (https=) 2022-05-02
JP7342030B2 JP7342030B2 (ja) 2023-09-11

Family

ID=66641471

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020559481A Active JP7342030B2 (ja) 2018-04-24 2019-04-22 ヒドロキシクエン酸および/またはその塩を使用してt細胞集団を産生する方法

Country Status (7)

Country Link
US (2) US12415845B2 (https=)
EP (1) EP3784774B1 (https=)
JP (1) JP7342030B2 (https=)
CN (2) CN118726256A (https=)
AU (1) AU2019260656B2 (https=)
CA (1) CA3097858A1 (https=)
WO (1) WO2019209715A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220004028A (ko) * 2019-04-26 2022-01-11 알로젠 테라퓨틱스 인코포레이티드 동종 car t 세포를 제조하는 방법
US12365871B2 (en) 2020-04-28 2025-07-22 Lyell Immunopharma, Inc. Methods for culturing cells
WO2022011129A1 (en) * 2020-07-09 2022-01-13 The Board Of Trustees Of The Leland Stanford University Multi-parallel analysis of t-cell therapies

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
US7915036B2 (en) 2004-09-13 2011-03-29 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions comprising T cell receptors and methods of use thereof
US7820174B2 (en) 2006-02-24 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services T cell receptors and related materials and methods of use
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
AU2008206442B2 (en) 2007-01-12 2012-10-18 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services gp100-specific T cell receptors and related materials and methods of use
WO2010088160A1 (en) 2009-01-28 2010-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US8465743B2 (en) 2009-10-01 2013-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
CN103124740B (zh) 2010-09-21 2015-09-02 美国卫生和人力服务部 抗-ssx-2t细胞受体和相关材料及使用方法
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
EP2694549B1 (en) 2011-04-08 2018-08-15 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
ES2834070T3 (es) 2011-09-15 2021-06-16 Us Health Receptores de células T que reconocen MAGE restringido por HLA-A1 o HLA-Cw7
WO2013059593A1 (en) 2011-10-20 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
US9359447B2 (en) 2012-03-23 2016-06-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
EA033110B1 (ru) 2012-04-11 2019-08-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы
JP6378172B2 (ja) 2012-05-22 2018-08-22 アメリカ合衆国 マウス抗ny−eso−1t細胞受容体
IL286786B (en) 2012-09-14 2022-09-01 The Us Secretary Department Of Health And Human Services Office Of Technology Transfer National Inst T cell receptors that recognize mhc mage–a3 are restricted type ii
CN104822705B (zh) 2012-10-24 2019-07-12 美国卫生和人力服务部 M971嵌合抗原受体
WO2014160627A1 (en) 2013-03-25 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
CN110511960B (zh) 2013-07-15 2023-05-23 美国卫生和人力服务部 抗人乳头瘤病毒16 e6 t细胞受体
AU2015209263A1 (en) 2014-01-24 2016-07-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-NY-BR-1 polypeptides, proteins, and chimeric antigen receptors
IL290655B2 (en) 2014-05-29 2024-05-01 Us Health Anti-human papillomavirus 16 E7 T-cell chelates
US10973894B2 (en) 2014-10-02 2021-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
AU2014407539B2 (en) 2014-10-02 2020-10-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation
JPWO2016067968A1 (ja) * 2014-10-29 2017-04-27 昭和電工株式会社 ミトコンドリア機能改善剤
GB201519340D0 (en) 2015-11-02 2015-12-16 Cambridge Entpr Ltd Methods of T-lymphocyte expansion
US20190321314A1 (en) 2016-09-15 2019-10-24 Memorial Sloan Kettering Cancer Center Inhibition of Acetyl-CoA Metabolism for Treatment and Prevention of Immune System Diseases and Disorders

Similar Documents

Publication Publication Date Title
Nallasamy et al. Tumor microenvironment enriches the stemness features: the architectural event of therapy resistance and metastasis
US20230383250A1 (en) Methods of cell culture for adoptive cell therapy
JP5894538B2 (ja) 炎症性ヒトTh17細胞の増殖および機能を決定的に調節するICOS
US20210085719A1 (en) Bispecific car t-cells for solid tumor targeting
CN103756964B (zh) 一种高效扩增cd3-cd56+的自然杀伤细胞培养系统的方法
TW202020141A (zh) 一種用於nk細胞體外擴增的培養基體系及nk細胞體外擴增的方法
IL274293B2 (en) Process for generating therapeutic compositions of engineered cells
JP2021521828A5 (https=)
JP2020534839A5 (https=)
Hu et al. Natural killer cell-based immunotherapy for cancer: advances and prospects
CN109121413A (zh) 使用靶向核酸纳米载体编程治疗性细胞的组合物和方法
JP2012521215A5 (https=)
JP2016524914A5 (https=)
JP2022505194A (ja) 組織常在メモリー様t細胞を生成するための方法及びその使用
WO2019206326A1 (zh) 改进的t细胞治疗方法
Lv et al. γδT cells, a key subset of T cell for cancer immunotherapy
Huang et al. T cell immune response within B-cell follicles
Fu et al. Efficacy of human iPSC-derived CAR-NK cells targeting multiple myeloma cells
Xiao et al. Engineered T cells stimulate dendritic cell recruitment and antigen spreading for potent anti-tumor immunity
Koppers et al. Chimeric antigen receptor-macrophages: Emerging next-generation cell therapy for brain cancer
Lin et al. Optimizing the procedure for manufacturing clinical-grade genetically manipulated natural killer cells for adoptive immunotherapy
Zhang et al. Research progress on tumor-infiltrating lymphocyte therapy for cervical cancer
CN112262212B (zh) 使用羟基柠檬酸和/或其盐产生t细胞群体的方法
JPWO2019209715A5 (https=)
Yang et al. CAR-M therapy in the era of tumor immunotherapy: current research progress and engineering strategies